Milestone Pharmaceuticals enrolls first European participant in ReVeRA-301 Phase 3
Milestone Pharmaceuticals announced the first European study participant has been enrolled in its ReVeRA-301 Phase 3 clinical trial.
Story updates
12:07:02 PM UTC
SquawkNews
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVRMONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. NASDAQ:MIST, a biopharmaceutical company focused on the development…